ND Biosciences was founded to develop next-generation therapeutics and diagnostics for neurodegenerative diseases (NDs). The therapies developed at ND Biosciences focus on treating both early and late stages of NDs. This is accomplished by developing combination therapies that prevent the initiation of pathological protein aggregation observed in NDs, and that neutralize the activities of existing protein aggregates. ND Biosciences has developed integrated proprietary platforms that enable its transformative drug discovery and preclinical development programs. These platforms are based on unique capabilities and model systems that allow ND Biosciences to: - Reverse-engineer the complexity of protein aggregates observed in NDs under controlled conditions - Model key processes underlying the formation of protein pathologies and neurodegeneration in living neurons - Develop novel companion diagnostic assays and imaging agents that capture the diversity and complexity of protein pathology in patient’s brains